13:00 EDT Marker CEO expects some patient data readout for MT-601 study by year-end
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRKR:
- Marker Therapeutics reports non-clinical proof of concept data on MT-401
- Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
- Biotech Alert: Searches spiking for these stocks today
- European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients
- Marker Therapeutics granted Orphan Drug Designation from EMA for MT-401